Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 3980 Premier Dr, Suite 310 HIGH POINT NC 27265 |
Tel: | N/A |
Website: | https://vtvtherapeutics.com |
IR: | See website |
Key People | ||
Paul Jai Sekhri President, Chief Executive Officer, Director | Steven Tuch Chief Financial Officer | Richard S. Nelson Executive Vice President - Corporate Development, Director |
Barry Brown Chief Accounting Officer | Thomas Strack Chief Medical Officer |
Business Overview |
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for diabetes. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non-central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes HPP593, Nrf2/Bach1 Modulator Program, Azeliragon and HPP3033. |
Financial Overview |
For the fiscal year ended 31 December 2023, vTv Therapeutics Inc revenues decreased from $2M to $0K. Net loss increased 6% to $20.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and Development - Balancing increase of 10% to $13.2M (expense), Other income (expense) - related party decrease of 39% to $574K (income). |
Employees: | 16 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $67.51M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$25.41M as of Dec 31, 2023 |
Net annual income (TTM): | -$20.25M as of Dec 31, 2023 |
Free cash flow (TTM): | -$19.08M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 2,662,322 as of Mar 13, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |